Aurobindo Pharma Ltd (BOM:524804)
₹ 1267.4 -20.45 (-1.59%) Market Cap: 736.11 Bil Enterprise Value: 739.33 Bil PE Ratio: 21.08 PB Ratio: 2.49 GF Score: 91/100

Q4 2023 Aurobindo Pharma Ltd Earnings Call Transcript

May 29, 2023 / 03:00AM GMT
Release Date Price: ₹611.2 (-0.55%)
Operator

Good morning, and welcome to Aurobindo Pharma Quarter 4 FY '23 Earnings Call. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to the management for opening remarks. Thank you, and over to you.

Deepti Thakur

Thank you, [Ambit]. Good morning, and a warm welcome to our fourth quarter FY '23 earnings call. I'm Deepti Thakur from the Investor Relations team. We hope you have received the quarter 4 FY '23 financials and the press release that was sent out on Saturday. These are also available on our website.

I would like to introduce my senior management team today on the call with us, represented by Dr. Satakarni Makkapati, CEO of Aurobindo Biosimilars, Vaccines and Peptide businesses; Mr. Yugandhar Puvvala, CEO of Eugia Pharma Specialities Limited; Mr. Sanjeev Dani, COO and Head Formulations, Aurobindo Pharma Limited; Mr. Swami Iyer, CEO, Aurobindo Pharma USA; and Mr. S. Subramanian, CFO.

We will begin the call with summary highlights from the management followed by an interactive Q&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot